LY2784544
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Myeloproliferative Disorders
Conditions
Myeloproliferative Disorders, Thrombocythemia, Essential, Polycythemia Vera, Primary Myelofibrosis
Trial Timeline
Apr 1, 2010 → Feb 22, 2018
NCT ID
NCT01134120About LY2784544
LY2784544 is a phase 1 stage product being developed by Eli Lilly for Myeloproliferative Disorders. The current trial status is completed. This product is registered under clinical trial identifier NCT01134120. Target conditions include Myeloproliferative Disorders, Thrombocythemia, Essential, Polycythemia Vera.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01520220 | Phase 1 | Completed |
| NCT01134120 | Phase 1 | Completed |
Competing Products
20 competing products in Myeloproliferative Disorders